Skybiotech Healthcare Ltd

Skybiotech Healthcare Ltd

BBSE:SKYBIOTECH
116.50
INR
-0.50
(-0.43%)
-7.89EPS
429.86MMarket Cap
Skybiotech Healthcare Ltd
BSE:SKYBIOTECH
(Bombay Stock Exchange)

Recent

price

116.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
- -
- -
- -
- -
0.51
- -
2.21
0.53
0.21
0.46
- -
- -
- -
- -
42.07
42.35
24.57
Revenue per Share
0.2
0.12
0.25
0.25
0.24
0.04
0.16
-0.04
-0.27
-0.36
-0.46
-0.36
-0.07
8.02
-14.18
-6.7
-7.89
Basic EPS, GAAP
- -
- -
- -
0.2
-0.23
-0.08
-0.03
3.08
0.43
-5.63
12.31
5.86
-3.59
-6.98
-8.19
-9.11
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
13.82
16.44
16.69
16.93
17.18
20.9
24.2
26.42
27.18
21.63
30.92
35.76
33.55
56.56
46.93
41.74
- -
Book Value per Share
13.82
16.44
16.69
16.93
17.18
20.9
24.2
26.42
27.18
21.63
30.92
35.76
33.55
56.56
30.34
25.16
- -
Tangible Book Value per Share
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
Basic Weighted Avg Shares
- -
- -
- -
- -
1
- -
2
1
- -
- -
- -
- -
- -
- -
70
71
52
Sales/Revenue/Turnover
- -
- -
- -
- -
15.66
- -
9.78
-22.5
-190.8
-107.38
- -
- -
- -
- -
-37.69
-27.37
-48.74
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
5
5
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15
-24
-11
-17
Net Income, GAAP
1.69
15.49
6.14
2.45
4.17
7.03
23.47
- -
- -
- -
- -
- -
- -
18.12
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
46.88
- -
7.27
-7.58
-127.69
-77.94
- -
- -
- -
- -
-33.7
-15.82
-32.13
Profit Margin (%)
1
7
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
82
-6
-5
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
70
82
- -
LT Debt
8
17
17
18
18
22
25
27
28
22
32
37
35
108
105
93
- -
Total Equity
1.41
0.95
1.51
1.46
1.43
0.22
0.71
- -
- -
- -
- -
- -
- -
-1.42
- -
- -
- -
Return on Invested Capital (%)
1.41
0.95
1.51
1.46
1.43
0.22
0.72
- -
- -
- -
- -
- -
- -
21.44
- -
- -
- -
Return on Capital (%)
1.41
0.95
1.51
1.46
1.43
0.22
0.71
-0.16
-1.02
-1.48
-1.76
-1.09
-0.2
21.44
-23.9
-13.15
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
9
- -
LT Borrowings
- -
82
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
- -
295
430

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
15
- -
Cash, Cash Equivalents & STI
- -
-6
- -
Accounts Receivable, Net
- -
11
- -
Inventories
- -
8
- -
Total Current Liabilities
- -
19
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
9
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.54%
41%
-12.19%
Free Cash Flow
-1,069.65%
11.64%
10.99%
Net Income, GAAP
-2,091.86%
-4,342.45%
-52.86%
Sales/Revenue/Turnover
- -
- -
0.44%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
16
25
10
70
2026
24
19
10
18
71
2027
5
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.79
-1.29
-2.06
-6.71
-14.18
2026
-0.1
-1.29
-2.53
-1.59
-6.7
2027
-2.56
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Business
Kapil Cotex Limited engages in textile and allied businesses in India, including spinning, weaving, and finishing of textiles; trading in fabrics such as denim, lace, satin, silk, and cotton; dealing in shares and securities; and providing consultancy services. Incorporated in 1983 and headquartered in Aurangabad, Maharashtra at Gut No. 5, Gavrai Tanda, the company operates primarily within India with registered offices in Mumbai and Chhatrapati Sambhaji Nagar (formerly Aurangabad). In April 2024, Kapil Cotex agreed to acquire a 72.51% stake in Skybiotech Lifesciences Private Limited, a move into biopharmaceuticals with the target reporting approximately INR 110 million in unaudited revenue for fiscal 2023-24; the transaction was approved by its board and expected to complete within 30 days. The company continues to report modest quarterly revenues, such as INR 24.23 million in a recent period amid ongoing net losses, while holding its 41st Annual General Meeting in September 2024 and scheduling board meetings for unaudited financial results through 2025, including appointments of additional directors and compliance officers.